Marnie Elizaga

Dr. Marnie Elizaga

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
SRStephen C. De Rosa
Stephen C. De Rosa
SESrilatha Edupuganti
Srilatha Edupuganti
YHYunda Huang
Yunda Huang
XHXue Han
Xue Han
MEMarnie Elizaga
Marnie Elizaga
MMM. Juliana McElrath
M. Juliana McElrath
BACKGROUND: HVTN 098, a randomized, double-blind, placebo-controlled trial, evaluated the safety, tolerability, and immunogenicity of PENNVAX-GP HIV DNA vaccine, administered with or without plasmid IL-12 (pIL-12), via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, HIV-uninfected adults. The study tested whether PENNVAX-GP delivered via ID/EP at one-fifth the dose could elicit equivalent immune responses to delivery via IM/EP and whether inclusion of pIL-12 provided additional benefit. METHODS: Participants received DNA encoding HIV-1 env/gag/pol in 3 groups: 1.6 mg ID (ID no IL-12 group, n = 20), 1.6 mg ID + 0.4 mg pIL-12 (ID + IL-12 group, n = 30), 8 mg IM + 1 mg pIL-12 (IM + IL-12 group, n = 30), or placebo ( n = 9) via EP at 0, 1, 3, and 6 months. Results of cellular and humoral immunogenicity assessments are reported. RESULTS: Following vaccination, the frequency of responders (response rate) to any HIV protein based on CD4 + T cells expressing IFN-γ or IL-2 was 96% for both the ID + IL-12 and IM + IL-12 groups; CD8 + T cell response rates were 64% and 44%, respectively. For ID delivery, the inclusion of pIL-12 increased CD4 + T cell response rate from 56% to 96%. The frequency of responders was similar (≥90%) for IgG binding antibody to gp140 consensus Env across all groups, but the magnitude was higher in the ID + IL-12 group compared with the IM + IL-12 group. CONCLUSION: PENNVAX-GP DNA induced robust cellular and humoral immune responses, demonstrating that immunogenicity of DNA vaccines can be enhanced by EP route and inclusion of pIL-12. ID/EP was dose sparing, inducing equivalent, or in some aspects superior, immune responses compared with IM/EP. TRIAL REGISTRATION: ClinicalTrials.gov NCT02431767. FUNDING: This work was supported by National Institute of Allergy and Infectious Diseases (NIAID), U.S. Public Health Service grants, an HIV Vaccine Design and Development Team contract, Integrated Preclinical/Clinical AIDS Vaccine Development Program, and an NIH award.

20 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MEMarnie Elizaga
Marnie Elizaga
SLShuying S. Li
Shuying S. Li
NKNidhi K. Kochar
Nidhi K. Kochar
GWGregory J. Wilson
Gregory J. Wilson
MAMary A. Allen
Mary A. Allen
OTon behalf of the NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team
on behalf of the NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team
The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. The objective of this study was to test the safety and tolerability of a novel prime-boost vaccine regimen incorporating these strategies with different doses of IL-12 plasmid DNA adjuvant. In a phase 1 study, 88 participants received an HIV-1 multiantigen (gag/pol, env, nef/tat/vif) DNA vaccine (HIV-MAG, 3000 μg) co-administered with IL-12 plasmid DNA adjuvant at 0, 250, 1000, or 1500 μg (N = 22/group) given intramuscularly with electroporation (Ichor TriGrid™ Delivery System device) at 0, 1 and 3 months; followed by attenuated recombinant vesicular stomatitis virus, serotype Indiana, expressing HIV-1 Gag (VSV-Gag), 3.4 ⊆ 107 plaque-forming units (PFU), at 6 months; 12 others received placebo. Injections were in both deltoids at each timepoint. Participants were monitored for safety and tolerability for 15 months. The dose of IL-12 pDNA did not increase pain scores, reactogenicity, or adverse events with the co-administered DNA vaccine, or following the VSV-Gag boost. Injection site pain and reactogenicity were common with intramuscular injections with electroporation, but acceptable to most participants. VSV-Gag vaccine often caused systemic reactogenicity symptoms, including a viral syndrome (in 41%) of fever, chills, malaise/fatigue, myalgia, and headache; and decreased lymphocyte counts 1 day after vaccination. HIV-MAG DNA vaccine given by intramuscular injection with electroporation was safe at all doses of IL-12 pDNA. The VSV-Gag vaccine at this dose was associated with fever and viral symptoms in some participants, but the vaccine regimens were safe and generally well-tolerated. Clinical Trials.gov NCT01578889.

7 December 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
SESrilatha Edupuganti
Srilatha Edupuganti
SRStephen C. De Rosa
Stephen C. De Rosa
MEMarnie Elizaga
Marnie Elizaga
YLYiwen Lu
Yiwen Lu
XHXue Han
Xue Han
TNThe Niaid-Funded Hiv Vaccine Trials Network
The Niaid-Funded Hiv Vaccine Trials Network
Background: Several techniques are under investigation to improve the immunogenicity of HIV-1 DNA vaccine candidates. DNA vaccines are advantageous due to their ease of design, expression of multiple antigens, and safety. Methods: The HVTN 098 trial assessed the PENNVAX®-GP DNA vaccine (encoding HIV env, gag, pol) administered with or without plasmid IL-12 at 0-, 1-, 3-, and 6-month timepoints via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, adult participants. We report on safety, tolerability, and acceptability. Results: HVTN 098 enrolled 94 participants: 85 received PENNVAX®-GP and nine received placebo. Visual analog scale (VAS) pain scores immediately after each vaccination were lower in the ID/EP than in the IM/EP group (medians 4.1–4.6 vs. 6–6.5, p < 0.01). IM/EP participants reported greater pain and/or tenderness at the injection site. Most ID/EP participants had skin lesions such as scabs/eschars, scars, and pigmentation changes, which resolved within 6 months in 51% of participants (24/55). Eighty-two percent of IM/EP and 92% of ID/EP participant survey responses showed acceptable levels of discomfort. Conclusions: ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants.

17 March 2023 in Vaccine
Verified
Journal Article
Closed access
GWGregory J. Wilson
Gregory J. Wilson
BRBenigno Rodriguez
Benigno Rodriguez
SLShuying Sue Li
Shuying Sue Li
MAMary Allen
Mary Allen
IFIan Frank
Ian Frank
MEMarnie Elizaga
Marnie Elizaga

3 July 2021 in Vaccine
Verified
Journal Article
Closed access
YHYunda Huang
Yunda Huang
KSKelly E. Seaton
Kelly E. Seaton
WMWilfredo Martin Casapia Morales
Wilfredo Martin Casapia Morales
LPLaura Polakowski
Laura Polakowski
SRStephen C. De Rosa
Stephen C. De Rosa
PGPaul Goepfert
Paul Goepfert